| P50 | author | Lance Miller | Q30505196 |
| | Carl F Blackman | Q42710297 |
| | Ralph B. D'Agostino Sr. | Q59209521 |
| | Boris Pasche | Q90575334 |
| | Hugo Jimenez | Q92500045 |
| P2093 | author name string | Kui Chen | |
| | Wei Zhang | |
| | Hui-Kuan Lin | |
| | Minghui Wang | |
| | Herbert L Bonkovsky | |
| | Liang Liu | |
| | Michael Olivier | |
| | Hui-Wen Lo | |
| | Guangxu Jin | |
| | Devin Absher | |
| | Richard M Myers | |
| | Dongquan Chen | |
| | Guang-Yu Yang | |
| | Zhi-Xiang Xu | |
| | Anand Ghanekar | |
| | David L Caudell | |
| | Kounosuke Watabe | |
| | Barry DeYoung | |
| | Dwayne W Godwin | |
| | Reginald Munden | |
| | Michael J Pennison | |
| | Philippe Merle | |
| | Myles Capstick | |
| | Yijian Gong | |
| | Alexandre Barbault | |
| | Sambad Sharma | |
| | Arthur W Blackstock | |
| | Ivan Brezovich | |
| | Jacquelyn W Zimmerman | |
| | Trevor Surratt | |
| P2860 | cites work | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Voltage-gated calcium channels | Q28242997 |
| | T-type calcium channels blockers as new tools in cancer therapies | Q28306311 |
| | Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 | Q29547403 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | STAR: ultrafast universal RNA-seq aligner | Q29615052 |
| | The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | Q29616215 |
| | Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. | Q30308083 |
| | Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis | Q30394806 |
| | T-type calcium channel blockers as neuroprotective agents | Q30415535 |
| | Normalization of RNA-seq data using factor analysis of control genes or samples | Q30844396 |
| | Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus | Q31068871 |
| | GC-content normalization for RNA-Seq data | Q34104119 |
| | RNA-SeQC: RNA-seq metrics for quality control and process optimization | Q34249292 |
| | Disruption of cancer cell replication by alternating electric fields | Q34318661 |
| | Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. | Q34631518 |
| | Cancer cell proliferation is inhibited by specific modulation frequencies | Q34634038 |
| | Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies | Q34657282 |
| | Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development | Q35595247 |
| | Cancer Stem Cells: From Bench to Bedside | Q35765724 |
| | Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach | Q37166421 |
| | Generation of subcutaneous and intrahepatic human hepatocellular carcinoma xenografts in immunodeficient mice | Q37604978 |
| | Ion channels and the hallmarks of cancer | Q37694856 |
| | Calcium in tumour metastasis: new roles for known actors. | Q37903657 |
| | Frequency decoding of calcium oscillations. | Q38165604 |
| | MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. | Q38294849 |
| | Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. | Q38610336 |
| | Disparities in liver cancer occurrence in the United States by race/ethnicity and state | Q38741005 |
| | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study | Q38787080 |
| | Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma | Q38812372 |
| | Development of a new generation of high-resolution anatomical models for medical device evaluation: the Virtual Population 3.0. | Q39141963 |
| | A role of functional T-type Ca2+ channel in hepatocellular carcinoma cell proliferation | Q39793964 |
| | Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice | Q40266452 |
| | Age-dependent impact of CaV 3.2 T-type calcium channel deletion on myogenic tone and flow-mediated vasodilatation in small arteries | Q42487284 |
| | Cancer statistics, 2018. | Q47191906 |
| | Use of non-ionizing electromagnetic fields for the treatment of cancer | Q48104513 |
| | Effects of modulated VHF fields on the central nervous system | Q48475158 |
| | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 |
| | At the crossroads of cancer stem cells and targeted therapy resistance. | Q53762158 |
| | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 |
| | Alternating Electric Fields (TTFields) Activate Ca1.2 Channels in Human Glioblastoma Cells | Q61813177 |
| | Induction of calcium-ion efflux from brain tissue by radiofrequency radiation: effect of sample number and modulation frequency on the power-density window | Q70935155 |
| | Calcium-ion efflux from brain tissue: power-density versus internal field-intensity dependencies at 50-MHz RF radiation | Q70935198 |
| | Guidelines for limiting exposure to time-varying electric, magnetic, and electromagnetic fields (up to 300 GHz). International Commission on Non-Ionizing Radiation Protection | Q74390933 |
| | Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 |
| | An HF exposure system for mice with improved efficiency | Q89106239 |
| | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q91147767 |
| | Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF | Q92294397 |
| P304 | page(s) | 209-224 | |
| P577 | publication date | 2019-05-31 | |
| P1433 | published in | EBioMedicine | Q24912341 |
| P1476 | title | Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx | |
| P478 | volume | 44 | |